The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

GSK has shifted towards a global marketing model ... Richardson noted that the streaming service has around nine different promotional photos for each programme – and an algorithm picks the ...

We consulted 12 of 16 clubs that made up Liga F in the 2023-24 season to find out about the state of top-flight women’s ...

Oluwafemi Adelakun has provided a detailed explanation of the numerous benefits of herbal medicine, highlighting its ...

GSK’s oral treatment Jesduvroq increases erythropoietin ... in clinical testing for treatment-resistant hypertension and chronic kidney disease. Image sourced from Dialysis Patient Citizens ...

Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...